Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease

Authors, Journal, Affiliations, Type, DOI

• Authors: Jinwei Tian, Zhuozhong Wang, Yan Wang, Fan Wang, Xiang Peng, Jiandong Xiao, Chunjie Li, Xinyu Hou, Qian Tong, Xi Yu, Guangren Gao, Peng Zhao, Jie Zhao, Ying Liu, Zhexue Qin, Haijing Lu, Shujiang Zhang, Shengli Li, Zhiyuan Weng, Huifang Tang, Yuquan He, Chunpeng Zhang, Yong Liu, Jun Jiang, Jinying Zhang, Lei Cai, Lili Xiu, Gary S. Mintz, Duolao Wang, Gregg W. Stone, Bo Yu, for the DAPT-MVD Trial Investigators
• Journal: New England Journal of Medicine (NEJM) 2026;395:233-242
• Affiliations: Harbin Medical University (lead), Cardiovascular Research Foundation (NY), Icahn School of Medicine at Mount Sinai, plus 20 Chinese centers
• Type: Phase 3, open-label, assessor-blinded, randomized controlled trial at 97 centers in China
• DOI: 10.1056/NEJMoa2517588
• ClinicalTrials.gov: NCT04624854

Overview

DAPT-MVD is a practice-changing Phase 3 RCT (n=8,250) conducted across 97 Chinese centers that tested whether extending DAPT with clopidogrel + aspirin from 12 to 24 months after DES implantation in patients with multivessel CAD would reduce ischemic events. All patients had remained event-free during the first 12 months of DAPT. Extended DAPT reduced the primary composite of CV death, nonfatal MI, or nonfatal stroke (HR 0.82; 95% CI 0.69–0.98; P=0.03), driven primarily by a 32% reduction in MI. Critically — and in contrast to all prior extended DAPT trials — there was no increase in clinically relevant bleeding (BARC ≥2: HR 0.89; P=0.54). The trial's distinctive features — clopidogrel-based DAPT, exclusively Chinese population with low obesity prevalence, 98.3% ACS presentation, and selection for low bleeding risk through 12-month event-free survival — define the population in whom extended clopidogrel DAPT provides ischemic benefit without bleeding penalty.

Keywords

Extended dual antiplatelet therapy, multivessel coronary artery disease, clopidogrel, drug-eluting stent, percutaneous coronary intervention, DAPT duration

Key Takeaways

BACKGROUND

• Multivessel CAD (prevalence 40–60% among PCI patients) increases ongoing risk of MI and death; thrombotic events often arise from untreated coronary segments beyond stented lesions.
• Patients with multivessel disease at low bleeding risk routinely receive 12 months of DAPT after DES implantation.
• Prior extended DAPT trials consistently showed ischemic benefit offset by increased major bleeding (DAPT Study, PEGASUS-TIMI 54).
• Guideline recommendation for extended DAPT in selected high-ischemic-risk patients is Class IIa; uncertainty remains about the optimal regimen and population.

METHODS — Trial Design

• Design: Open-label, assessor-blinded, randomized trial at 97 centers in China.
• Sponsor: National Natural Science Foundation of China, Chinese Society of Cardiology, Lepu Medical Technology.
• Population: Adults 18–75 years with multivessel CAD (≥2 major epicardial arteries with ≥50% stenosis; left main ≤30%) who remained event-free for 12 months after DES implantation without major ischemic or bleeding events.
• Exclusion: Planned anticoagulant use; contraindications to P2Y12 inhibitors.
• Randomization: 1:1 to extended DAPT (clopidogrel 75 mg + aspirin 75–150 mg daily) or aspirin monotherapy (75–150 mg daily) for an additional 12 months.
• Post-trial treatment: After the 12-month protocol period (2 years post-PCI), antiplatelet regimen selected by treating physician; nearly all patients received aspirin monotherapy.
• Follow-up: Clinical/telephone at 1, 3, 6, 9, 12, and 36 months post-randomization; median 34.3 months.
• Primary efficacy endpoint: Composite of CV death, nonfatal MI, or nonfatal stroke (time-to-first-event).
• Primary safety endpoint: Clinically relevant or major bleeding (BARC type ≥2).
• Key secondary endpoints: All-cause death, CV death, nonfatal MI, nonfatal stroke, net adverse clinical event (ischemic + BARC 2–5), stent thrombosis, urgent/any revascularization.

Statistical Analysis

• Sample size: 8,250 patients → 80% power to detect 20% lower risk (HR 0.80) assuming 5% annual event rate in aspirin group, 5% loss to follow-up, 3% nonadherence.
• Primary analysis: Intention-to-treat with unadjusted Cox regression.
• Covariate-adjusted analysis: age, sex, BMI, diabetes, hypertension, hyperlipidemia, smoking, alcohol use.
• Sensitivity: per-protocol, site-level random effects, win ratio hierarchical analysis.

RESULTS

Participants

• Between October 2020 and March 2024: 9,127 assessed → 8,250 randomized (4,125 per group).
• Mean time from index PCI to randomization: 378.6±19.8 days.
• Pre-randomization DAPT: aspirin + clopidogrel (67.1%) or aspirin + ticagrelor (32.9%).
• Baseline characteristics (well-balanced): Mean age 61 years; 30.3% women; 28.2% diabetes; 98.3% presented with ACS before index PCI (34.0% MI); 79.5% single-vessel PCI, 20.5% multivessel PCI.
• Median follow-up: 34.3 months; lost to follow-up: 1.8%.
• Major protocol deviations: 2.2% (2.1% nonadherence).

Primary Efficacy Endpoint

• CV death, nonfatal MI, or nonfatal stroke: 222 (5.8%) vs 266 (6.8%); HR 0.82 (95% CI 0.69–0.98; P=0.03).
• Covariate-adjusted HR: 0.82 (95% CI 0.68–0.98) — consistent.
• Win ratio: 1.22 (95% CI 1.01–1.46) — consistent with primary analysis.
• Benefit became apparent after month 6 of extended therapy and sustained for 12 months after treatment cessation (landmark analysis).
• Per-protocol and sensitivity analyses consistent.

Secondary Efficacy Endpoints

• Nonfatal MI: 67 (1.8%) vs 97 (2.5%); HR 0.68 (95% CI 0.50–0.93) — primary driver of benefit.
• Nonfatal stroke: 97 (2.5%) vs 120 (3.1%); HR 0.80 (95% CI 0.61–1.04).
• All-cause death: 120 (3.1%) vs 116 (3.0%); HR 1.02 (95% CI 0.79–1.32) — NO difference.
• CV death: 73 (2.0%) vs 75 (1.9%); HR 0.96 (95% CI 0.70–1.33).
• Net adverse clinical event: 255 (6.7%) vs 295 (7.5%); HR 0.85 (95% CI 0.72–1.01).
• Stent thrombosis: 0 vs 2 (0% vs 0.1%).
• MI benefit driven by fewer events from nontarget coronary segments rather than stented target sites — suggesting plaque stabilization effect beyond stent-related thromboprophylaxis.

Primary Safety Endpoint

• BARC ≥2 bleeding: 51 (1.4%) vs 57 (1.5%); HR 0.89 (95% CI 0.61–1.30; P=0.54) — NO increase.
• BARC ≥3 bleeding: 29 (0.8%) vs 33 (0.9%); HR 0.87 (95% CI 0.53–1.43; P=0.59).
• Serious adverse events: 27.7% vs 28.0% (P=0.77).

Subgroup and Landmark Analyses

• Primary endpoint effect consistent across prespecified subgroups.
• Possible exception: patients with high BMI — known predictor of impaired clopidogrel response (ABCD-GENE score).
• Landmark analysis: clinical benefit emerged after month 6, sustained ≥12 months after treatment cessation → suggests disease-modifying effect beyond direct antithrombotic action (P2Y12-mediated plaque stabilization, reduced lipid accumulation in vascular smooth muscle cells, prevention of macrophage iron overload).

DISCUSSION — Why No Bleeding Increase?

The trial is distinctive in showing ischemic benefit without bleeding penalty — in contrast to all prior extended DAPT trials. Key factors:

1. Clopidogrel (not ticagrelor/prasugrel) as the P2Y12 inhibitor — less potent, lower bleeding risk.
2. Exclusively Chinese population — lower obesity prevalence; clopidogrel metabolized more efficiently in non-obese persons; CYP2C19 loss-of-function alleles prevalent in East Asians (reduces clopidogrel bioactivation → may increase ischemic events captured).
3. Selection of low bleeding risk: 12-month event-free survival requirement enriched for patients at favorable risk–benefit balance.
4. Nonelderly population (mean age 61; excluded >75 years).
5. Stroke burden notably high (stroke events nearly equal to MI events) — consistent with East Asian CAD epidemiology where cerebrovascular disease is proportionally greater.

Limitations

• Open-label design — mitigated by blinded endpoint adjudication.
• Exclusively Chinese population — clopidogrel pharmacogenomics and low obesity prevalence may limit generalizability to Western populations; extended DAPT with clopidogrel may have greater ischemic benefit and higher bleeding risk in Western populations.
• Clopidogrel + aspirin vs aspirin only — does not inform about ticagrelor monotherapy or clopidogrel monotherapy alternatives.
• Lower-than-anticipated event rate (2.2% at 12 months vs assumed 5% annually) — the trial still met its primary endpoint, but absolute benefit is modest (1.0% ARR at 36 months; NNT ~100).
• Strokes rather than coronary events comprised a substantial proportion of events — reflecting the trial's epidemiology and infrequent use of high-sensitivity troponins in China (more unstable angina diagnoses).
• Patients at lower ischemic risk or higher bleeding risk not represented — results apply specifically to multivessel CAD patients who survived 12 months event-free.
• 5.8% residual ischemic risk on extended DAPT underscores that clopidogrel-based DAPT is insufficient to fully eliminate long-term risk — future strategies may incorporate anti-inflammatory or lipid-lowering intensification.

Key Concepts Mentioned

• concepts/DAPT-Strategies — DAPT-MVD extends evidence for extended clopidogrel-based DAPT in a selected high-ischemic, low-bleeding-risk multivessel CAD population
• concepts/Multivessel-PCI-STEMI-Timing — related multivessel CAD interventional strategy
• concepts/Fractional-Flow-Reserve — related coronary physiology in multivessel disease

Key Entities Mentioned

• entities/Acute-Coronary-Syndrome — 98.3% ACS presentation
• entities/Chronic-Coronary-Disease — post-12-month phase of post-ACS management

Wiki Pages Updated

• wiki/sources/DAPT-MVD-NEJM-2026.md — created (this page)
• wiki/concepts/DAPT-Strategies.md — DAPT-MVD data added to extended DAPT section; contradictions updated
• wiki/sourceindex.md — source entry added
• wiki/wikiindex.md — no new concepts (DAPT strategies already indexed)
• log.md — ingest entry appended